|
|
|
|
|||||
|
|
|
By Daniella Parra
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) said its Enhanced Brain Delivery (EBD) bispecific antibodies showed improved brain penetration in the treatment of Alzheimer’s disease.
The company said it is collaborating with JCR Pharmaceuticals Co., Ltd. on EBD candidate development and studies through transferrin receptor-mediated delivery across both mouse and non-human primate models.
“Confirming our mouse data in non-human primates is a pivotal step for our EBD program,” said Paul Shughrue, PhD, Vice President, Program Leader and Head of Research, Acumen Pharmaceuticals. “The degree of brain penetration we observed in cynomolgus monkeys, combined with preserved soluble amyloid beta oligomer selectivity and a clean hematological profile, exceeded our expectations and gives us strong confidence in the differentiated potential of our EBD program’s approach.”
Contact:
Click HERE to follow us on LinkedIn
The post Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights appeared first on ExecEdge.
| Jul-20 | |
| Jul-16 | |
| Jul-15 | |
| Jul-15 | |
| Jul-07 | |
| Jun-16 | |
| Jun-16 | |
| May-12 | |
| May-12 | |
| May-07 | |
| May-05 | |
| Mar-27 | |
| Mar-26 | |
| Mar-26 | |
| Mar-19 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite